Trial · NCT04625985
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Viral load | Day 0 to Day 28 or patient discharge day | Assess differences in SARS-CoV-2 viral load between participants that receive placebo vs metformin glycinate |
| Primary | consciousness level | Day 0 to Day 28 or patient discharge day | Clinical status assessed by measurement of consciousness level: alertness |
| Primary | temperature | Day 0 to Day 28 or patient discharge day | Clinical status assessed by measurement of axillary body temperature in °C: \<37.2. |
| Primary | systolic blood pressure | Day 0 to Day 28 or patient discharge day | Clinical status assessed by measurement of systolic blood pressure in mmHg: \>90. |
| Primary | Oxigen saturation | Day 0 to Day 28 or patient discharge day | Clinical status assessed by measurement of oxygen saturation in %: \>90. |
| Primary | Heart rate | Day 0 to Day 28 or patient discharge day | Clinical status assessed by measurement of heart rate in beats per minute: \<100 bpm. |
| Primary | respiratory rate | Day 0 to Day 28 or patient discharge day | Clinical status assessed by measurement of respiratory rate in breaths per minute: \<24 bpm, |
| Primary | Days of hospitalization | Day 0 to Day 28 or patient discharge day | Assess length of hospitalization |
| Primary | Days of supplementary oxygen if applies | Day 0 to Day 28 or patient discharge day | Assess length of supplementary oxygen |
| Primary | Days of supplementary mechanical ventilation | Day 0 to Day 28 or patient discharge day | Assess length of mechanical ventilation |
| Secondary | Toxicity of study drug assessed by incidence of adverse events (grade 3 or 4) | Day 0 to Day 28 or patient discharge day | Assess by incidence of Grade 3, Grade 4, and Serious Adverse Events (AEs) |
| Secondary | Changes in laboratory test results | Day 0 to Day 28 or patient discharge day | Changes in serum levels from security laboratories compared to baseline levels and between groups. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04625985/registered